Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.5 USD | -2.52% | +2.85% | -18.85% |
Jun. 03 | Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating | MT |
Jun. 03 | Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.85% | 1.41B | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Citigroup Adjusts Arcus Biosciences Price Target to $41 From $40, Maintains Buy Rating